Compare LRMR & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LRMR | ALEC |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.5M | 275.8M |
| IPO Year | 2014 | 2019 |
| Metric | LRMR | ALEC |
|---|---|---|
| Price | $3.03 | $2.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 7 |
| Target Price | ★ $14.40 | $3.90 |
| AVG Volume (30 Days) | 1.3M | ★ 2.0M |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.70 |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | $900.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.52 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.92 | $1.09 |
| 52 Week High | $6.42 | $2.84 |
| Indicator | LRMR | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 59.82 | 61.48 |
| Support Level | $2.89 | $1.90 |
| Resistance Level | $4.19 | $2.65 |
| Average True Range (ATR) | 0.25 | 0.23 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 95.93 | 64.22 |
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.